MCC950 may inhibit inflammasome priming by downregulating nuclear factor kappa B and caspase-1, which are key components of inflammasome activation.59 Treatment with MCC950 also reduced NLRP3 expression and IL-1β release while improving short-term memory deficits in a blast exposure rat model.60 Neurodegenerative disease is associated with NLRP3 inflammation, and utilizing MCC950 has also been of interest in animal models to potentially reduce risk for chronic neurodegenerative disease. Here, NLRP3 is linked to neurodegenerative disease.